Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study
RecruitingOBSERVATIONAL
Enrollment
60
Participants
Timeline
Start Date
May 24, 2022
Primary Completion Date
September 30, 2027
Study Completion Date
September 30, 2027
Conditions
HER2-positive Breast Cancer
Trial Locations (1)
104-0045
RECRUITING
National Cancer Center Hospital, Japan, Chuo-ku
All Listed Sponsors
lead
National Cancer Center, Japan
OTHER_GOV
NCT05433753 - Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study | Biotech Hunter | Biotech Hunter